By Nina Kienle
Roche said its blood cancer drug Gazyva/Gazyvaro demonstrated positive results in patients with primary membranous nephropathy, a rare, autoimmune kidney disease.
The Swiss drugmaker on Monday said that results from a late-stage trial showed statistically significant and clinically meaningful benefits, reflecting that more patients achieved complete remission at two years.
The drug is already approved in the U.S. and the European Union for the treatment of adults with active lupus nephritis, as well as in 100 countries for various types of haematological cancers, Roche said.
The company will present results at an upcoming medical meeting, it added.
Write to Nina Kienle at nina.kienle@wsj.com
(END) Dow Jones Newswires
02-16-26 0139ET
